戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 onses underlying lithium-induced nephrogenic diabetes insipidus.
2 ion, and its perturbation is associated with diabetes insipidus.
3 another three patients due to development of diabetes insipidus.
4 ions or downregulation can cause nephrogenic diabetes insipidus.
5 rkedly reduced, ameliorating the symptoms of diabetes insipidus.
6 in AVP-expressing neurons, developed central diabetes insipidus.
7 ible with a diagnosis of partial nephrogenic diabetes insipidus.
8 ndling of water in health and in nephrogenic diabetes insipidus.
9  might be necessary in patients with central diabetes insipidus.
10 treatment of mice and a patient with central diabetes insipidus.
11 a (increased water intake), both features of diabetes insipidus.
12 autoreactive CD8 T cells can trigger central diabetes insipidus.
13 ing, the absence of which causes nephrogenic diabetes insipidus.
14 s a potential therapeutic use in nephrogenic diabetes insipidus.
15 main of the human vasopressin gene can cause diabetes insipidus.
16  defect and hypernatremic dehydration due to diabetes insipidus.
17 essin analog), characteristic of nephrogenic diabetes insipidus.
18 alleles responsible for X-linked nephrogenic diabetes insipidus.
19 ing from congenital cataracts to nephrogenic diabetes insipidus.
20  mice produces distinct forms of nephrogenic diabetes insipidus.
21 he pathogenesis of familial neurohypophyseal diabetes insipidus.
22 t tissue and nodal involvement, and four had diabetes insipidus.
23 a, twins or triplets, or subclinical central diabetes insipidus, a transient diabetes insipidus may e
24 story of diabetes, diabetic ketoacidosis, or diabetes insipidus; a need for renal replacement therapy
25 Autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI) is a progressive, inherited
26 autosomal dominant familial neurohypophyseal diabetes insipidus (adFNDI), a rare inherited disorder t
27      Despite a paucity of published reports, diabetes insipidus after discontinuation of vasopressin
28                             The mechanism of diabetes insipidus after discontinuation of vasopressin
29 dy was to investigate the occurrence rate of diabetes insipidus after discontinuation of vasopressin
30                  Sixteen of 29 patients with diabetes insipidus after discontinuation of vasopressin
31                 To date, very few reports of diabetes insipidus after discontinuation of vasopressin
32                       The occurrence rate of diabetes insipidus after discontinuation of vasopressin
33   Our findings demonstrate the occurrence of diabetes insipidus after discontinuation of vasopressin
34 effect of donor hyperosmolarity secondary to diabetes insipidus, an almost universal occurrence among
35 e an autosomal recessive form of nephrogenic diabetes insipidus and absence of the Colton blood group
36 Drug Administration (FDA) in 1978 for use in diabetes insipidus and bleeding disorders, but it is als
37  mutations in aquaporins include nephrogenic diabetes insipidus and congenital cataracts.
38 ent for bipolar disorder, causes nephrogenic diabetes insipidus and hypercalcemia in about 20% and 10
39  diabetes mellitus, optic atrophy, deafness, diabetes insipidus and neurological signs.
40 re renal side effects, including nephrogenic diabetes insipidus and rarely, ESRD.
41 ts identify a novel mechanism of nephrogenic diabetes insipidus and uncover a role of SOCE in renal w
42 at diagnosis, diagnosis of low-grade glioma, diabetes insipidus, and central precocious puberty were
43 icant risk factor for lower scores, but sex, diabetes insipidus, and cranial radiotherapy were not.
44 eases such as Gaucher's disease, nephrogenic diabetes insipidus, and Creutzfeldt-Jakob disease.
45 enerative origin of optic atrophy, deafness, diabetes insipidus, and incontinence, (2) other previous
46 dentified growth hormone deficiency, central diabetes insipidus, and male hypogonadism as new feature
47           Improvement in bone lesions, pain, diabetes insipidus, and other manifestations was gradual
48 function, including hypochloremic alkalosis, diabetes insipidus, and salt-sensitive hypotension, with
49 attleboro rats, with hereditary hypothalamic diabetes insipidus, and Sprague-Dawley rats, with normal
50       Fourteen months post-OLT she developed diabetes insipidus, bilateral ear discharge, and new ost
51 n in magnocellular cells or a side effect of diabetes insipidus, but favors the hypothesis that centr
52 renal distal tubular acidosis or nephrogenic diabetes insipidus can be caused by autoantibodies targe
53 ed with several disorders, including central diabetes insipidus (CDI).
54  optic atrophy which is often accompanied by diabetes insipidus, deafness, urological and neurologica
55       Furthermore, in a patient with central diabetes insipidus, desmopressin reduced the excretion o
56                                Unexpectedly, diabetes insipidus developed in surviving animals.
57 increased susceptibility for lithium-induced diabetes insipidus development.
58                                              Diabetes insipidus (DI) is a disorder characterized by e
59 in is indicated for the treatment of central diabetes insipidus (DI), bedwetting, haemophilia A and v
60 ary activity based on the absence of central diabetes insipidus (DI).
61 X receptor beta (LXRbeta) in the etiology of diabetes insipidus (DI).
62 eatures subsequently emerged, and "DIDMOAD" (diabetes insipidus, diabetes mellitus, optic atrophy, an
63 ble organ donors without clinically apparent diabetes insipidus display a defect in the baroreflex-me
64 , it might have utility in treating forms of diabetes insipidus (e.g., X-linked nephrogenic diabetes
65 tis pigmentosa, color blindness, nephrogenic diabetes insipidus, familial ACTH resistance, and famili
66                    Familial neurohypophyseal diabetes insipidus (FNDI) in humans is an autosomal domi
67                    Familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant disor
68 autosomal dominant familial neurohypophyseal diabetes insipidus (FNDI).
69 nent damage by the primary disease, LCH (eg, diabetes insipidus, fractures, and tooth loss).
70 veloped as the disease progressed, including diabetes insipidus, growth hormone deficiency, primary h
71 nt inhibitor of GSK3beta, causes nephrogenic diabetes insipidus, GSK3beta may play a crucial role in
72 2 receptor and aquaporin 2 cause nephrogenic diabetes insipidus; however, expression of these genes i
73 ascular complications, visual complications, diabetes insipidus, hypopituitarism and cranial nerve in
74 etal defects in 42%, dental problems in 30%, diabetes insipidus in 25%, growth failure in 20%, sex ho
75          Other features included nephrogenic diabetes insipidus in 87% and hypertension in 33.3%.
76 irst susceptibility gene for lithium-induced diabetes insipidus in mice.
77 d distal tubular toxicity caused nephrogenic diabetes insipidus in one.
78 ifferentiation (which could explain acquired diabetes insipidus in patients receiving lithium) is unc
79 abetes insipidus (e.g., X-linked nephrogenic diabetes insipidus) in which the kidney responds inappro
80 hich is associated with familial nephrogenic diabetes insipidus, induces constitutive arrestin-mediat
81  most common cause of hereditary nephrogenic diabetes insipidus is a nonfunctional vasopressin (VP) r
82                                              Diabetes insipidus is a syndrome characterized by excret
83                    Familial neurohypophyseal diabetes insipidus is an autosomal dominant disorder cha
84 Autosomal dominant familial neurohypophyseal diabetes insipidus is caused by mutations in the arginin
85                                Postoperative diabetes insipidus is common after pituitary surgery and
86                             This nephrogenic diabetes insipidus leads to dehydration and death of nur
87 tan, a VR2 blocker that causes a nephrogenic diabetes insipidus-like excessive loss of hypotonic urin
88 ver, proAVP misfolding in hereditary central diabetes insipidus likely shares common physiopathologic
89        To reduce lithium-induced nephrogenic diabetes insipidus (lithium-NDI), patients with bipolar
90 erimental iron overload leads to nephrogenic diabetes insipidus marked by AVP-resistant urinary conce
91 ical central diabetes insipidus, a transient diabetes insipidus may ensue from this vasopressinase-me
92   Mechanisms underlying the pathogenicity of diabetes insipidus mutations were probed by studying the
93  (AQP2) point mutants that cause nephrogenic diabetes insipidus (NDI) are retained in the endoplasmic
94  models of a variety of acquired nephrogenic diabetes insipidus (NDI) disorders have identified a com
95                       Congenital nephrogenic diabetes insipidus (NDI) is a rare disease caused most o
96                                  Nephrogenic diabetes insipidus (NDI) is caused by impairment of vaso
97          Hereditary non-X-linked nephrogenic diabetes insipidus (NDI) is caused by mutations in the a
98 ety of animal models of acquired nephrogenic diabetes insipidus (NDI) that loss of the aquaporin-2 (A
99 n family with partial congenital nephrogenic diabetes insipidus (NDI) that resulted from a mutation i
100 utations that cause non-X-linked nephrogenic diabetes insipidus (NDI) were characterized to establish
101 nts treated with lithium develop nephrogenic diabetes insipidus (NDI), a disorder characterized by po
102 ary concentrating ability, i.e., nephrogenic diabetes insipidus (NDI), but the molecular mechanism is
103 ting a transgenic mouse model of nephrogenic diabetes insipidus (NDI), we have analyzed the mouse aqu
104 defective trafficking results in nephrogenic diabetes insipidus (NDI).
105  can produce autosomal recessive nephrogenic diabetes insipidus (NDI).
106 ion in mice with lithium-induced nephrogenic diabetes insipidus (NDI).
107                       Congenital nephrogenic diabetes insipidus (NDI; also known as arginine vasopres
108 re of the possibility of sevoflurane-induced diabetes insipidus not only during general anesthesia bu
109 ism, while central adrenal insufficiency and diabetes insipidus occurred in some patients.
110 lex, followed by a hyperdynamic response and diabetes insipidus, occurred in every animal following b
111 ore is the treatment of choice for transient diabetes insipidus of pregnancy.
112 ively, hypoarousal could be a side effect of diabetes insipidus - polydipsia and polyuria seen in Hom
113                    One patient developed new diabetes insipidus post-operatively.
114 The mice had severe polyuria and nephrogenic diabetes insipidus, potentially due to greatly reduced A
115 roved in many countries for the treatment of diabetes insipidus, primary nocturnal enuresis, nocturia
116 Our findings establish a form of nephrogenic diabetes insipidus produced by impaired water permeabili
117 with these effects, Grhl2-deficient mice had diabetes insipidus, produced dilute urine, and failed to
118 associated with Charcot-Marie-Tooth disease, diabetes insipidus, retinitis pigmentosa, cystic fibrosi
119                  He was later diagnosed with diabetes insipidus, spastic quadriplegia, developmental
120 hree children affected with neurohypophyseal diabetes insipidus, suggesting autosomal recessive inher
121                              The nephrogenic diabetes insipidus symptoms and the absence of developme
122  (AdAVP) in an AVP-deficient animal model of diabetes insipidus (the Brattleboro rat), which allowed
123 that a molecular determinant for nephrogenic diabetes insipidus, the vasopressin receptor with a subs
124                                              Diabetes insipidus was evaluated in 21 patients; it was
125 id organ donors without clinical evidence of diabetes insipidus; we also investigated the vasopressor
126 shing phenomenon, hyperdynamic response, and diabetes insipidus were observed in each animal after BD
127 nfusion for treatment of shock, criteria for diabetes insipidus were observed in two of 1,320 subject
128 n to be responsible for X-linked nephrogenic diabetes insipidus were used as model systems.
129 hormone arginine vasopressin (AVP) underlies diabetes insipidus, which is characterized by the excret
130 -) mice represent a new model of nephrogenic diabetes insipidus with unique molecular etiology, and w
131 mutation known to cause X-linked nephrogenic diabetes insipidus (XNDI) in humans (Glu242stop) into th
132                         X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease cau

 
Page Top